The DOI matches its Crossref record.
Chemotherapy of Thyroid Cancer with Adriamycin: Experience with 30 Patients
Abstract
Thirty patients with advanced refractory metastatic thyroid carcinoma received chemotherapy with adriamycin at a starting dose of 45 to 75 mg per square meter intravenously every three weeks. Eleven patients demonstrated a greater than 50 per cent decrease in the size of their metastases. Subjective improvement, particularly relief of pain from bony metastases, was also observed. Histologic cell types responding included medullary (solid) (three of five), papillary-follicular (three of 10), Hürthle cell (two of five), spindle and giant cell (two of nine) and unclassified thyroid carcinoma (one of one). Although the rate of disease progression in the responding and nonresponding patients was similar before the start of adriamycin, the median survival from this point on was significantly superior (p<0.005) in the responders (median 11 + and range of over five to 40 + months, six of 11 living) to that of the nonresponders (median four and range of 0.1 to 23 + months, five of 19 living). Before the need to limit the total cumulative dose of adriamycin delivered to 550 mg per square meter was recognized, adriamycin-induced cardiomyopathy developed in three patients, but this side effect has not been observed since that limitation. Adriamycin appears to be a promising regimen for patients with progressive metastatic thyroid carcinoma. (N Engl J Med 290:193–197, 1974)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Metadata
- Authors
- Gottlieb, J. A., & Hill, C. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1974-01-24
- Volume
- 290
- Issue
- 4
- Pages
- 193-197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329319370
- Cited by
- 235
- References
- 0
- FWCI
- 11.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy of Thyroid Cancer with Adriamycin: Experience with 30 Patients. https://app.cochat.ai/papers/10.1056/nejm197401242900404
- The paper
- Gottlieb, J. A., & Hill, C. S. (1974). Chemotherapy of Thyroid Cancer with Adriamycin: Experience with 30 Patients. New England Journal of Medicine. https://doi.org/10.1056/nejm197401242900404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.